Today's Volume: 773,000
Average Volume: 745,007Volume % Change: 67% From a technical perspective, CRI is spiking higher here back above its 50-day moving average of $58.31 with above-average volume. This move has also started to push shares of CRI into breakout territory, since the stock has taken out some near-term overhead resistance at $58.48. Traders should now look for long-biased trades in CRI as long as it's trending above its 50-day at $58.31 or above today's low of $57.37, and then once it sustains a move or close above $58.48 with volume that hits near or above 745,007 shares. If CRI can maintain this trend, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $61 to its 52-week high at $61.22. Viacom Viacom (VIA.B) is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. Its products include Nexavar, Stivarga and Kyprolis. This stock is trading up 1% to $62.15 in recent trading. Today's Volume: 2.42 million Average Volume: 3.07 million Volume % Change: 50% Shares of VIAB are trending up modestly here after Susquehanna raised its price target on the stock from $65 to $71 because of a compelling combination of improving operating trends as well as a low P/E. From a technical perspective, VIAB is trending up slightly here right above its 50-day moving average of $60.01 with decent upside volume. This move is quickly pushing shares of VIAB within range of triggering a near-term breakout trade. That trade will hit if VIAB manages to take out some near-term overhead resistance at $62.80 to $63 with high volume. Traders should now look for long-biased trades in VIAB as long as it's trending above today's low of $61.88 and then once it sustains a move or close above those breakout levels with volume that hits near or above 3.07 million shares. If that breakout hits soon, then VIAB will set up to re-test or possibly take out its 52-week high at $64.71.